SeoulCRO   Report issue

For profit Phase 4
Founded: Seoul Korea, Republic of (2009)
Status: No NME R&D (2009)

Organization Overview

First Clinical Trial
2014
NCT02204722
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 4 Trials (1)

imatinib (gleevec) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 4)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 4)

Leukemia, Myeloid (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 1
  • # of Trial APIs: 1